Vascular smooth muscle inhibition

Vascular smooth muscle inhibition refers to therapeutic or physiological actions that prevent the contraction or proliferation of vascular smooth muscle cells. VSMC contraction is initiated chiefly by increased intracellular calcium that triggers a cascade involving calmodulin and myosin light chain kinase, resulting in myosin phosphorylation and actin-myosin cross-bridge cycling[1][3][7]. Proliferative responses are mediated by growth factors and cell cycle regulators, with excessive VSMC proliferation contributing to vascular pathologies such as atherosclerosis, restenosis, and hypertension[4][6]. Drugs like rapamycin, statins, and certain kinase inhibitors inhibit these pathways, reducing disease progression but presenting safety challenges such as delayed endothelial repair[2][4][6]. In summary, "vascular smooth muscle inhibition" is a process, not a distinct molecular target, and is used to describe the actions of various drugs or signaling mechanisms involved in cardiovascular therapy.

Other names

Vascular smooth muscle cell inhibitionVSMC inhibitionAnti-proliferative activity in vascular smooth muscleVascular relaxation (context-dependent)

Inhibition of myosin light chain kinase (MLCK) or its pathway, preventing myosin light chain phosphorylation[1][3][5][7] Increasing cyclic AMP or activating protein kinase A, leading to relaxation[1] Inhibition of mTOR pathway (Rapamycin), inhibiting proliferation/differentiation programs[6] Modulation of PPARγ signaling to suppress cell cycle progression[4] Inhibition of receptor-mediated calcium signaling (e.g., blockade of L-type calcium channels)[1][7]